Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity.

Machado RF, Barst RJ, Yovetich NA, Hassell KL, Kato GJ, Gordeuk VR, Gibbs JS, Little JA, Schraufnagel DE, Krishnamurti L, Girgis RE, Morris CR, Rosenzweig EB, Badesch DB, Lanzkron S, Onyekwere O, Castro OL, Sachdev V, Waclawiw MA, Woolson R, Goldsmith JC, Gladwin MT; walk-PHaSST Investigators and Patients.

Blood. 2011 Jul 28;118(4):855-64. doi: 10.1182/blood-2010-09-306167. Epub 2011 Apr 28.

2.

Pulmonary hypertension associated with hemoglobinopathies: prevalent but overlooked.

Farmakis D, Aessopos A.

Circulation. 2011 Mar 22;123(11):1227-32. doi: 10.1161/CIRCULATIONAHA.110.988089. Review. No abstract available.

3.

[Pulmonary complications in adult sickle cell disease].

Maître B, Mekontso-Dessap A, Habibi A, Bachir D, Parent F, Godeau B, Galacteros F.

Rev Mal Respir. 2011 Feb;28(2):129-37. doi: 10.1016/j.rmr.2010.08.013. Epub 2011 Feb 16. Review. French.

PMID:
21402228
4.

Diagnostic accuracy of echocardiography for pulmonary hypertension: a systematic review and meta-analysis.

Janda S, Shahidi N, Gin K, Swiston J.

Heart. 2011 Apr;97(8):612-22. doi: 10.1136/hrt.2010.212084. Epub 2011 Feb 25. Review. Erratum in: Heart. 2011 Jul;97(13):1112.

PMID:
21357375
5.

An elevated estimated pulmonary arterial systolic pressure, whenever measured, is associated with excess mortality in adults with sickle cell disease.

Lorch D, Spevack D, Little J.

Acta Haematol. 2011;125(4):225-9. doi: 10.1159/000323464. Epub 2011 Feb 1. No abstract available.

PMID:
21282944
7.

Vascular risk assessment in patients with sickle cell disease.

Morris CR.

Haematologica. 2011 Jan;96(1):1-5. doi: 10.3324/haematol.2010.035097. No abstract available.

8.

Frequency of pulmonary hypertension in asymptomatic β-thalassemia major patients and the role of physiological parameters in evaluation.

Kiter G, Balci YI, Ates A, Hacioglu S, Sari I.

Pediatr Hematol Oncol. 2010 Nov;27(8):597-607. doi: 10.3109/08880018.2010.503338.

PMID:
20795768
9.

Pulmonary hypertension in thalassemia.

Morris CR, Vichinsky EP.

Ann N Y Acad Sci. 2010 Aug;1202:205-13. doi: 10.1111/j.1749-6632.2010.05580.x.

PMID:
20712794
10.

Pulmonary hypertension in smoking mice over-expressing protease-activated receptor-2.

De Cunto G, Cardini S, Cirino G, Geppetti P, Lungarella G, Lucattelli M.

Eur Respir J. 2011 Apr;37(4):823-34. doi: 10.1183/09031936.00060210. Epub 2010 Aug 6.

11.

Pulmonary hypertension and NO in sickle cell.

Gladwin MT, Barst RJ, Castro OL, Gordeuk VR, Hillery CA, Kato GJ, Kim-Shapiro DB, Machado R, Morris CR, Steinberg MH, Vichinsky EP.

Blood. 2010 Aug 5;116(5):852-4. doi: 10.1182/blood-2010-04-282095. No abstract available.

12.

Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective.

Machado RF, Gladwin MT.

Chest. 2010 Jun;137(6 Suppl):30S-38S. doi: 10.1378/chest.09-3057.

13.

Tobacco smoke: a risk factor for pulmonary arterial hypertension? A case-control study.

Schiess R, Senn O, Fischler M, Huber LC, Vatandaslar S, Speich R, Ulrich S.

Chest. 2010 Nov;138(5):1086-92. doi: 10.1378/chest.09-2962. Epub 2010 May 14.

PMID:
20472864
14.

Pulmonary hypertension and nitric oxide depletion in sickle cell disease.

Bunn HF, Nathan DG, Dover GJ, Hebbel RP, Platt OS, Rosse WF, Ware RE.

Blood. 2010 Aug 5;116(5):687-92. doi: 10.1182/blood-2010-02-268193. Epub 2010 Apr 15. Review.

15.

Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study.

Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S, Saned MS, El-Chafic AH, Fasulo MR, Cappellini MD.

Blood. 2010 Mar 11;115(10):1886-92. doi: 10.1182/blood-2009-09-243154. Epub 2009 Dec 23.

16.

Cardiac mortality in {beta}-thalassemia major: resting but not dobutamine stress echocardiography predicts mortality among initially cardiac disease-free patients in a prospective 12-year study.

Hahalis G, Kourakli A, Gerasimidou I, Kalogeropoulos AP, Sitafidis G, Papageorgiou U, Davlouros P, Grapsas N, Zoumbos NC, Alexopoulos D.

Eur J Heart Fail. 2009 Dec;11(12):1178-81. doi: 10.1093/eurjhf/hfp152. Epub 2009 Nov 4.

17.

ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association.

McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J; American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc; Pulmonary Hypertension Association.

J Am Coll Cardiol. 2009 Apr 28;53(17):1573-619. doi: 10.1016/j.jacc.2009.01.004. No abstract available.

18.

Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation.

Minniti CP, Sable C, Campbell A, Rana S, Ensing G, Dham N, Onyekwere O, Nouraie M, Kato GJ, Gladwin MT, Castro OL, Gordeuk VR.

Haematologica. 2009 Mar;94(3):340-7. doi: 10.3324/haematol.13812. Epub 2009 Feb 11.

19.

Mechanisms of vasculopathy in sickle cell disease and thalassemia.

Morris CR.

Hematology Am Soc Hematol Educ Program. 2008:177-85. doi: 10.1182/asheducation-2008.1.177. Review.

PMID:
19074078
20.

Pulmonary hypertension in beta-thalassemia major and the role of L-carnitine therapy.

El-Beshlawy A, Youssry I, El-Saidi S, El Accaoui R, Mansi Y, Makhlouf A, Taher A.

Pediatr Hematol Oncol. 2008 Dec;25(8):734-43. doi: 10.1080/08880010802244035.

PMID:
19065439

Supplemental Content

Support Center